Nuvalent (NUVL) Equity Average (2020 - 2026)
Nuvalent (NUVL) reported Equity Average of $1.2 billion for Q1 2026, up 16.43% on a YoY basis from $1.0 billion in Q1 2025, and up 15.71% quarter-over-quarter from $1.0 billion in Q4 2025.
Nuvalent (NUVL) Equity Average (2020 - 2026) Analysis & Trends
Nuvalent has reported Equity Average for 7 years, with the latest figure at $1.2 billion in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 16.43% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 16.43% YoY), and the FY2025 full-year result was $1.2 billion, up 30.94% from the prior year.
- Equity Average for Q1 2026 stood at $1.2 billion, up from $1.0 billion in the prior quarter.
- The five-year high for Equity Average was $1.2 billion in Q1 2026, with the low at $244.8 million in Q3 2022.
- Historically, Equity Average has averaged $674.1 million across 5 years, with a median of $656.0 million in 2024.
- Annual changes were most pronounced in 2022 — Equity Average surged 891.95% — and 2025, when it declined 4.44%.
- Nuvalent's Equity Average stood at $349.8 million in 2022, then jumped by 56.75% to $548.3 million in 2023, then soared by 99.8% to $1.1 billion in 2024, then fell by 4.44% to $1.0 billion in 2025, then grew by 15.71% to $1.2 billion in 2026.
- The last three Equity Average figures came in at $1.2 billion (Q1 2026), $1.0 billion (Q4 2025), and $892.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 516.41 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 1.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.21 Bn |
| Dec 31, 2025 | 1.05 Bn |
| Sep 30, 2025 | 892.57 Mn |
| Jun 30, 2025 | 975.40 Mn |
| Mar 31, 2025 | 1.04 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Sep 30, 2024 | 879.08 Mn |
| Jun 30, 2024 | 656.04 Mn |
| Mar 31, 2024 | 687.80 Mn |
| Dec 31, 2023 | 548.27 Mn |
| Sep 30, 2023 | 408.57 Mn |
| Jun 30, 2023 | 432.56 Mn |
| Mar 31, 2023 | 453.47 Mn |
| Dec 31, 2022 | 349.78 Mn |
| Sep 30, 2022 | 244.78 Mn |
| Jun 30, 2022 | 260.95 Mn |
| Mar 31, 2022 | 276.98 Mn |
| Dec 31, 2021 | 293.08 Mn |
| Sep 30, 2021 | 126.70 Mn |
| Jun 30, 2021 | -43.18 Mn |